NCT01491932 - Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias | Biotech Hunter

Enrollment

129

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

DyskinesiasParkinson DiseaseMovement DisordersParkinsonian DisordersAnti-Dyskinesia Agents

Interventions

DRUG

AFQ056

AFQ056 will be supplied as oral capsules.

Trial Locations (32)

3010

Novartis Investigative Site, Bern

7400

Novartis Investigative Site, Kaposvár

12163

Novartis Investigative Site, Berlin

14547

Novartis Investigative Site, Beelitz-Heilstätten

20014

Novartis Investigative Site, Donostia / San Sebastian

25123

Novartis Investigative Site, Brescia

26655

Novartis Investigative Site, Westerstede/Oldenburg

28006

Novartis Investigative Site, Madrid

33604

Novartis Investigative Site, Pessac

34128

Novartis Investigative Site, Kassel

44791

Novartis Investigative Site, Bochum

53233

Novartis Investigative Site, Milwaukee

56126

Novartis Investigative Site, Pisa

59037

Novartis Investigative Site, Lille

63003

Novartis Investigative Site, Clermont-Ferrand

66160

Novartis Investigative Site, Kansas City

80113

Novartis Investigative Site, Englewood

81675

Novartis Investigative Site, München

82606

Novartis Investigative Site, Bratislava

83305

Novartis Investigative Site, Bratislava

A-6020

Novartis Investigative Site, Innsbruck

A-4020

Novartis Investigative Site, Linz

A-1220

Novartis Investigative Site, Vienna

N6A 4G5

Novartis Investigative Site, London

04103

Novartis Investigative Site, Leipzig

07646

Novartis Investigative Site, Stadtroda

H-6725

Novartis Investigative Site, Szeged

00163

Novartis Investigative Site, Roma

00179

Novartis Investigative Site, Roma

08036

Novartis Investigative Site, Barcelona

08190

Novartis Investigative Site, Sant Cugat del Vallès

08025

Novartis Investigative Site, Barcelona